STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
Sponsor: Beth Israel Deaconess Medical Center
This PHASE2 trial investigates Esophagogastric Cancer and is currently completed. Beth Israel Deaconess Medical Center leads this study, which shows 10 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Dec 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- Synta Pharmaceuticals Corp.
For direct contact, visit the study record on ClinicalTrials.gov .